By Benjamin Chiou
Date: Wednesday 03 Jan 2024
(Sharecast News) - C4X Discovery, the AIM-listed drug discovery company, has received a "milestone payment" of $11m from biopharma giant AstraZeneca as part of the progress of its NRF2 Activator programme, causing shares to jump by nearly a half on Wednesday.
By Josh White
Date: Wednesday 22 Feb 2023
(Sharecast News) - C4X Discovery launched a new precision medicine platform called 'PatientSeek' on Wednesday, after a successful research collaboration with the Garvan Institute of Medical Research.
By Josh White
Date: Thursday 19 Jan 2023
(Sharecast News) - C4X Discovery updated on its 'MALT-1' inhibitor programme on Thursday, explaining that the overexpression or over-activation of MALT-1 has been observed in a range of lymphomas and leukemias such as MALT lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia.
Currency | UK Pounds |
Share Price | 9.64p |
Change Today | -0.36p |
% Change | -3.60 % |
52 Week High | 21.45 |
52 Week Low | 8.14 |
Volume | 1,605,845 |
Shares Issued | 252.23m |
Market Cap | £24.31m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:41 | 400,000 @ 9.50p |
16:20 | 5,000 @ 9.90p |
16:16 | 2,006 @ 9.31p |
15:53 | 25,000 @ 9.36p |
15:45 | 20,000 @ 9.36p |
You are here: research